Several possible candidates, including tumor-infiltrating T lymphocyte quantification, immunostaining-based PD-L1, and sequencing-based mutational burden and neoantigen burden biomarkers, have been proposed for further evaluation (29, 30). Here, CD274 is linked to neoplasm.